Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07402369 | Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia | PHASE2 | RECRUITING | 120 | — | — | Feb 19, 2026 | Dec 31, 2027 | Mar 11, 2026 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| CMS-D002 Capsules 10 mg | EXPERIMENTAL | CMS-D002 Capsules 10 mg, QD |
| CMS-D002 Capsules 25 mg | EXPERIMENTAL | CMS-D002 Capsules 25 mg, QD |
| CMS-D002 Capsules 50 mg | EXPERIMENTAL | CMS-D002 Capsules 50 mg, QD |
| Placebo | PLACEBO_COMPARATOR | Placebo, QD |
| Name | Type | Description |
|---|---|---|
| CMS-D002 Capsules 10 mg | DRUG | CMS-D002 Capsules 10 mg, QD |
| CMS-D002 Capsules 25 mg | DRUG | CMS-D002 Capsules 25 mg, QD |
| CMS-D002 Capsules 50 mg | DRUG | CMS-D002 Capsules 50 mg, QD |
| Placebo | DRUG | Placebo, QD |
Inclusion Criteria: * 1.Non-menopausal females aged 18-50 years. * 2\. Body Mass Index (BMI) ≥ 18 kg/m². * 3\. Participant was diagnosed with uterine fibroids by ultrasound at the time of screening, and has one or more fibroids with a diameter of at least 2 cm (longest diameter). * 4\. Participant'...